Neurology® Podcast

1) Zika virus-associated Guillain-Barre Syndrome Variant in Haiti2 e-Pearl topic: Juvenile Huntington Disease3) Topic of the month: Clinical Trials Plenary Session at the AAN meeting about 5-HT6 antagonist as adjunctive therapy to cholinesterase inhibitors in patients with mild-to-moderate Alzheimer diseaseThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Stephen Donahue interviews Dr. Aaron Berkowitz about his paper on Zika virus-associated Guillain-Barre syndrome variant in Haiti. Dr. Ilena George is reading our e-Pearl of the week about juvenile Huntington disease. Dr. Alberto Espay interviews Dr. Alireza Atri about his Clinical Trials Plenary Session at the AAN meeting about 5-HT6 antagonist as adjunctive therapy to cholinesterase inhibitors in patients with mild-to-moderate Alzheimer disease.DISCLOSURES: Dr. Berkowitz receives royalties from the publication of the book: Clinical Pathophysiology Made Ridiculously Simple and the book: The Improvising Mind; received funding for travel from Stevens Institute of Technology; received speaker honorarium from Audio Digest; and received honorarium for recorded CME lecture.Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.

Dr. Ted Burns interviews Dr. Clinton Wright about his paper on leisure time physical activity and how it is associated with cognitive decline. Dr. Alberto Espay interviews Dr. Jeremy Schmahmann about his Frontiers in Neuroscience Plenary Session at the AAN meeting about the implications for neurology and psychiatry in the treatment of cerebellar cognitive affective syndrome.

Plenary Session Interviews - May 2016

Migraine updates and discussion on the topics of migraine genetics, science behind lifestyle factors, science behind lifestyle factors and clinical trials - July 2016

1) Low-cost, tablet-based option for prehospital neurologic assessment: the iTREAT Study2) What's Trending: Interview with Dafne Horovitz about her paper on cranial bone collapse in microcephalic infants prenatally exposed to Zika virus infection3) Topic of the month: Controversies in Neurology Plenary Session at the AAN meeting about the pro and con effects of cognitive enhancing activities and their effects on preventing dementiaThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kevin Barrett interviews Dr. Andy Southerland about his paper on a low-cost, tablet-based option for prehospital neurologic assessment. Dr. Ted Burns is interviewing Dr. Dafne Horovitz for our "What's Trending" feature of the week about her paper on cranial bone collapse in microcephalic infants prenatally exposed to Zika virus infection. Dr. Alberto Espay interviews Drs. Dave Knopman and Kaycee Sink about their Controversies in Neurology Plenary Session at the AAN meeting about the pro and con effects of cognitive enhancing activities and their effects on preventing dementia.DISCLOSURES: Dr. Barrett serves as Associate Editor for Neurohospitalist; serves as an editorial board member for Neurology®; receives royalties from the publications of the books Stroke and Neurology in Practice [Edited book]; and receives research support from the NIH.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: "Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;" and gave legal expert review.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Horovitz serves as Associate Editor for Journal of Community Genetics; received speaker honoraria from Biomarin Pharmaceutical, Genzyme-Sanofi, Shire Pharmaceuticals, Inc. and Alexion Pharmaceuticals, Inc.; received funding for travel to medical meeting from Genzyme-Sanofi and Shire Pharmaceuticals, Inc.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Knopman serves on the scientific advisory board for Consultant Bluefield project, Lundbeck Pharmaceuticals Inc., DIAN study DSMB; served as Associate Editor for Neurology® until October 2015; receives research support from the NIH, Mayo Alzheimer's Disease Research Center, Mayo Alzheimer Disease Patient Registry, ARIC Dementia Study and Chronic Kidney Disease and Cognitive functioning; received funding for travel to two lectures Alzheimer Conference, Seoul Korea and Behavioral Neurology Conference, Hyderabad, India.Dr. Sink served on the data safety monitoring board for two NIH funded clinical trials; initiated grants from the Alzheimer's Association and the Donald W. Reynolds Foundation as an investigator; received research support from the NIH.

1) Quality improvement in neurology: Parkinson disease update quality measurement set2) What's Trending: Amyloid pathology and axonal injury after brain trauma 3) Topic of the month: George C. Cotzias Lecture at the AAN Meeting on antibody mediated disorders of the synapseThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Binit Shah interviews Drs. Janis Miyasaki and Stewart Factor about the AAN paper on new quality measures developed to improve outcomes for patients with Parkinson disease. Dr. Ted Burns is interviewing Dr. Ansgar Furst for our "What's Trending" feature of the week about his editorial on incidental findings for what's to come in amyloid plaques in traumatic brain injury. Dr. Alberto Espay interviews Dr. Josep Dalmau about his George C. Cotzias Lecture at the AAN Meeting on the topic of antibody mediated disorders of the synapse.DISCLOSURES: Dr. Miyasaki received honoraria and funding for travel from Teva Pharmaceutical Industries Ltd.; received funding for travel from Merz Pharmaceuticals, LLC; received travel honoraria from The International Parkinson Disease and Movement Disorders Society; is a consultant for Merz Pharmaceuticals, LLC; receives royalties from the publication of the book "Psychogenic Movement Disorders;" receives research support from PCORI: 2015-2018 and Parkinson Alberta.Dr. Factor served as an editorial board member of Neurotherapeutics; serves on the data safety monitoring board for Lundbeck, Inc; is a consultant for UCB; is a consultant and video reviewer for clinical trials for Avanir, Neurocrine and Auspex/Teva Pharmaceutical Industries Ltd.; receives royalties from the publications of the books "Parkinson's disease diagnosis and clinical management" and "Drug induced movement disorders;" gave expert testimony in Kmart trial (2014-2016); receives research support from Ceregene, Cynapsus, Sangamo, Teva Pharmaceutical Industries Ltd., Ipsen Pharmaceuticals, Inc., USWorldMeds, Allergen, Inc., Medtronics, Inc., Auspex, Genzyme Corporation, Michael J. Fox Foundation and the NIH.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Dalmau serves as Editor of Neurology®: Neuroimmunology & Neuroinfammation; serves as an Editorial board member of Neurology® and UpToDate; receives royalties from patents for the use of Ma2 and NMDAR as autoantibody tests; is a consult for Advance Medical, receives research support from Euroimmun and the NIH; receives revenue from Euroimmun for the following tests: NMDA receptor autoantibody test, GABA(B)R autoantibody test, GABA(A)R autoantibody test, DPPX autoantibody test and Iglon5 autoantibody test.

1) Neurology® Genetics: Clinical and genetic features of cervical dystonia in a large multi-center cohort 2) What's Trending: Amyloid pathology and axonal injury after brain trauma 3) Topic of the month: Abstract presentation at the AAN meeting on the spectrum of multiple sclerosis misdiagnosis in the era of McDonald criteriaThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Fullard interviews Dr. Mark LeDoux about his Neurology: Genetics paper on the clinical and genetic features of cervical dystonia. Dr. Ted Burns is interviewing Dr. Dave Sharp for our "What's Trending" feature of the week about his paper on amyloid pathology and axonal injury after brain trauma. Dr. Andy Southerland interviews Dr. Andy Solomon about his abstract presentation at the AAN meeting on the spectrum of multiple sclerosis misdiagnosis in the era of McDonald criteria.DISCLOSURES: Dr. LeDoux serves on the scientific advisory boards of Spastic Paraplegia Foundation; serves as Chairman on the board of medical advisors of the National Spasmodic Torticollis Association; serves as an editorial board member of Parkinsonism and Related Disorders, Tremor and other hyperkinetic movement disorders, PLOS ONE and Neurology®; is a consultant for Azilect Advisory Board, Mayo Clinic, Teva Pharmaceutical Industries Ltd., Lundbeck Inc.; serves on the speakers' bureau of Teva Pharmaceutical Industries Ltd. and Lundbeck Inc.; receives funding for travel from Teva Pharmaceutical Industries Ltd. and Lundbeck Inc.; receives royalties from the publication of the books "Animal models of movement disorders" and "Movement disorders: Genetics and models;" receives research support from Benign Essential Blepharospasm Research FDN, CHDI, Enroll HD, Omeros, Phase 2, Auspex, US WorldMeds, Mysticol, Protocol, Accorda and the NIH.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Sharp receives research support from UK Medical Research Council, European Union, Wellcome Trust, Rosetrees Trust, Action Medical Research, Public engagement grant from The Physiological Society, The Royal Society Summer Science Exhibition and the NIH (UK).Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: "Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;" and gave legal expert review.Dr. Solomon received research support from the Portland Veterans Affairs Medical Center Fellowship in Multiple Sclerosis and Neuroimmunology and Partners Multiple Sclerosis Fellowship Award.NO CME WILL BE OFFERED THIS WEEK.

1) APOE-e4 and the associations of seafood and long-chain omega-3 fatty acids with cognitive decline 2) e-Pearl topic: Ocular neuromyotonia3) Topic of the month: Neurology Today story about Neurology Today story about new Center for Disease Control guidelines on prescribing opioids (Part 2)This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Prof. Martha Morris about her paper on APOE-e4 and the associations of seafood and long-chain omega-3 fatty acids with cognitive decline. Dr. Adam Numis is reading our e-Pearl of the week about ocular neuromyotonia. Dr. Ted Burns interviews Dr. Gary Franklin about a Neurology Today story on the topic of the new Center for Disease Control guidelines on prescribing opioids (Part 2).DISCLOSURES: Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials.Prof. Morris is a consultant for Neurotrack; serves on the scientific advisory board for the University of Chicago; received funding for travel from the University of California; receives research support from the Abbott Fund and the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Franklin serves as an editorial board member of Neuroepidemiology; serves on the Levels of Evidence Team for Neurology®; is a consultant for the California State Compensation Insurance Fund; receives research support from the Centers for Disease Control and Prevention.

1) Natural history of cavernous malformation: Systematic review and meta-analysis of 25 studies2) e-Pearl topic: Neurologic manifestations of hereditary hemorrhagic telangiectasia3) Topic of the month: Neurology Today story about new Center for Disease Control guidelines on prescribing opioids (Part 1)This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matthew Flaherty interviews Dr. Loch Macdonald about his paper on review and meta-analysis of 25 studies about the natural history of cavernous malformation. Dr. Adam Numis is reading our e-Pearl of the week about neurologic manifestations of hereditary hemorrhagic telangiectasia. Dr. Ted Burns interviews Dr. Gary Franklin about a Neurology Today story on the topic of the new Center for Disease Control guidelines on prescribing opioids (Part 1).DISCLOSURES: Dr. Flaherty serves on the scientific advisory board for DSMB member, I-DEF Trial (NINDS sponsored ICH treatment trial); has a patent pending, non-invasive CNS monitor; owns company stock as co-founder of SENSE Diagnostics, LLC (our product is currently investigational and not on the market); serves on the speakers' bureau of CSL Behring and Janssen; receives research support from American Heart Association, Pfizer Inc, Bristol-Myers Squibb, NIH and as Principal Investigator of a phase II, NINDS funded trial testing recombinant activated factor VII for treatment of intracerebral hemorrhage where study drug is supplied by Novo Nordisk.Dr. Macdonald serves as an editorial board member of Stroke, Journal of Neurosurgery, Neurosurgery, Journal of cerebral blood flow and metabolism, Neurocritical care, World Neurosurgery, Surgical Neurology International, Translational stroke research and Cerebrovascular diseases; treats unruptured aneurysm patients (1% effort); holds stock options in Edge Therapeutics, Inc; has a patent for treatment of delayed cerebral ischemia and subdural hemorrhage, intracranial drug delivery systems; receives research support from Canadian Institutes of Health Research, Brain Aneurysm Foundation, Heart and Stroke Foundation of Canada and Physicians Services Incorporated Foundation.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Franklin serves as an editorial board member of Neuroepidemiology; serves on the Levels of Evidence Team for Neurology®; is a consultant for the California State Compensation Insurance Fund; receives research support from the Centers for Disease Control and Prevention.

1) Variability in Physician Prognosis and Recommendations after Intracerebral Hemorrhage2) e-Pearl topic: Eye and facial findings in psychogenic non-epileptic seizures 3) Topic of the month: Neurology Today story about lead crisis in Flint exposing continuing risk to children nationwideThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Javier Provencio interviews Dr. Darin Zahuranec about his paper on variability in physician prognosis and recommendations after intracerebral hemorrhage. Dr. Adam Numis is reading our e-Pearl of the week about eye and facial findings in psychogenic non-epileptic seizures. Dr. Ted Burns interviews Dr. Chris Holstege about a Neurology Today story on the topic of lead crisis in Flint exposes continuing risk to children nationwide: What neurologists should know and what they can do about it.DISCLOSURES: Dr. Provencio serves on the scientific advisory boards for Minnetronix, INC., Advanced Circulatory, Inc; serves on the data safety monitoring board for the ASTROH trial; Received honoraria and funding for travel from Bard, Inc.; serves as an editorial board member of Journal of Neuroimmunology; receives royalties from the publication of the book Family guide toSurviving the ICU; served on the board of directors of the Neurocritical Care Society; serves as President for the Ohio Chapter of the Society of Critical Care Medicine; receives research support From Bard Inc., Systemic Normothermia in ICH (SNICH), Crothermics INC. and the NIH.Dr. Zahuranec receives research support from Medtronic, Inc. and the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.